Prague Med. Rep. 2023, 124, 199-215
https://doi.org/10.14712/23362936.2023.16
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer
References
1. Afatinib (2012) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000ClinPharmR.pdf (Accessed 10 March 2023)
2. Alectinib (2016) Committee for Medicinal Products for Human Use. European Medicines Agency. Alecensa. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
3. , A., Scholar, E. M. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–979.
<https://doi.org/10.1124/jpet.105.084145>
4. Brigatinib (2017) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation NDA 208772 ALUNBRIG (brigatinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf (Accessed 10 March 2023)
5. , K., Comisar, C., Witjes, H., Maringwa, J., de Greef, R., Vishwanathan, K., Cantarini, M., Cox, E. (2017) Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br. J. Clin. Pharmacol. 83, 1216–1226.
<https://doi.org/10.1111/bcp.13223>
6. Capmatinib (2022) Committee for Medicinal Products for Human Use. European Medicines Agency. Tabrecta. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/tabrecta-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
7. , A., Sureda, M., Brugarolas-Masllorens, A., Escudero-Ortiz, V. (2021) Therapeutic drug monitoring of erlotinib in non-small cell lung carcinoma: A case study. Ther. Drug Monit. 43, 447–450.
<https://doi.org/10.1097/FTD.0000000000000894>
8. Ceritinib (2014) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf (Accessed 11 March 2023)
9. , J., Ruiz-Garcia, A., James, L. P., Peltz, G., Thurm, H., Clancy, J., Hibma, J. (2021) Lorlatinib exposure-response analyses for safety and efficacy in a phase I/II trial to support benefit-risk assessment in non-small cell lung cancer. Clin. Pharmacol. Ther. 110, 1273–1281.
<https://doi.org/10.1002/cpt.2228>
10. , W. A., Chatelut, E., Fotoohi, A. K., Larson, R. A., Martin, J. H., Mathijssen, R. H. J., Salamone, S. J. (2021) Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur. J. Cancer 157, 428–440.
<https://doi.org/10.1016/j.ejca.2021.08.033>
11. , P., Cross, D., Jänne, P. A. (2021) Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat. Rev. Drug Discov. 20, 551–569.
<https://doi.org/10.1038/s41573-021-00195-4>
12. Crizotinib (2011) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf (Accessed 11 March 2023)
13. Dabrafenib (2013) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000ClinPharmR.pdf (Accessed 11 March 2023)
14. Dacomitinib (2018) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multi-disciplinary Review and Evaluation NDA 212725 VIZIMPRO (dacomitinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf (Accessed 11 March 2023)
15. , D., Guchelaar, H. J., den Hartigh, J., Gelderblom, H., van Erp, N. P. (2015) Individualized dosing of tyrosine kinase inhibitors: Are we there yet? Drug Discov. Today 20, 18–36.
<https://doi.org/10.1016/j.drudis.2014.09.007>
16. Entrectinib (2019) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multi-disciplinary Review and Evaluation NDA 212725 ROZLYTEK (entrectinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf (Accessed 11 March 2023)
17. Erlotinib (2021) Product Monograph Tarceva (erlotinib). Available at: https://www.rochecanada.com/PMs/Tarceva/Tarceva_PM_E.pdf (Accessed 11 March 2023)
18. , A., Hopkins, A. M., Sorich, M. J., Rowland, A. (2021) Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: A review of the literature. Expert Opin. Drug Metab. Toxicol. 17, 803–821.
<https://doi.org/10.1080/17425255.2021.1943357>
19. Gefitinib (2008) Committee for Medicinal Products for Human Use. European Medicines Agency. Iressa. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/iressa-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
20. , L., Louveau, B., Baroudjian, B., Allayous, C., Jouenne, F., Da Meda, L., Vu, L. T., Sauvageon, H., Herms, F., Delyon, J., Lebbé, C. Mourah, S. (2021) Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: A pharmacokinetic-pharmacodynamic real-life study. Cancer Chemother. Pharmacol. 88, 427–437.
<https://doi.org/10.1007/s00280-021-04299-x>
21. , J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., Pirl, W. F. (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21, 354–376.
<https://doi.org/10.1634/theoncologist.2015-0405>
22. , S. L., Mathijssen, R. H. J., Beijnen, J. H., Huitema, A. D. R., Steeghs, N. (2019) Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur. J. Clin. Pharmacol. 75, 1309–1318.
<https://doi.org/10.1007/s00228-019-02704-2>
23. , S. L., Geel, D. R., Janssen, J. M., de Vries, N., Rosing, H., Beijnen, J. H., Burgers, J. A., Smit, E. F., Huitema, A. D. R., Steeghs, N. (2021) Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small cell lung cancer patients. Clin. Pharmacol. Ther. 109, 394–402.
<https://doi.org/10.1002/cpt.1989>
24. , N., Largajolli, A., Witjes, H., Diderichsen, P. M., Zhang, S., Hanley, M. J., Lin, J., Mehta, M. (2022) Mobocertinib dose rationale in patients with metastatic NSCLC with EGFR exon 20 insertions: Exposure-response analyses of a pivotal phase I/II study. Clin. Pharmacol. Ther. 112, 327–334.
<https://doi.org/10.1002/cpt.2622>
25. , M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., Ferrante, K., Von Hoff, D. D., Silberman, S., Rowinsky, E. K. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267–3279.
<https://doi.org/10.1200/JCO.2001.19.13.3267>
26. , T., Muraki, S., Ieiri, I. (2019) Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin. Pharmacokinet. 58, 403–420.
<https://doi.org/10.1007/s40262-018-0689-7>
27. , L., Jiang, S., Shi, Y. (2020) Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J. Hematol. Oncol. 13, 143.
<https://doi.org/10.1186/s13045-020-00977-0>
28. , J. M., Dorlo, T. P. C., Steeghs, N., Beijnen, J. H., Hanff, L. M., van Eijkelenburg, N. K. A., van der Lugt, J., Zwaan, C. M., Huitema, A. D. R. (2020) Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin. Pharmacol. Ther. 108, 494–505.
<https://doi.org/10.1002/cpt.1808>
29. , J. S., Lee, M. H. (2009) Overview of therapeutic drug monitoring. Korean J. Intern. Med. 24, 1–10.
<https://doi.org/10.3904/kjim.2009.24.1.1>
30. , E. A., de Langen, A. J., Peters, B. J. M. (2019) Treatment of oncogene-driven non-small cell lung cancer. Curr. Opin. Pulm. Med. 25, 300–307.
<https://doi.org/10.1097/MCP.0000000000000572>
31. , H., Imamura, C. K., Kawamura, T., Oyakawa, T., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Taira, T., Naito, T., Murakami, H., Yamamoto, N., Takahashi, T., Tanigawara, Y. (2022) Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients. Cancer Chemother. Pharmacol. 90, 115–123.
<https://doi.org/10.1007/s00280-022-04452-0>
32. , N. A., Knapen, L. M., Schellens, J. H., Beijnen, J. H., Steeghs, N., Huitema, A. D. (2014) Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther. Drug Monit. 36, 326–334.
<https://doi.org/10.1097/FTD.0000000000000004>
33. Larotrectinib (2018) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation NDA 210861 and NDA 211710 VITRAKVI (larotrectinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_211710Orig1s000MultidisciplineR.pdf (Accessed 11 March 2023)
34. Larotrectinib (2019) Committee for Medicinal Products for Human Use. European Medicines Agency. Vitrakvi. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
35. , C. K., Wei, Y. F., Tsai, M. S., Chen, K. Y., Shih, J. Y., Yu, C. J. (2018) Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go? Eur. J. Cancer 103, 32–40.
<https://doi.org/10.1016/j.ejca.2018.07.128>
36. , J., Fettner, S., Lum, B. L., Riek, M., Rakhit, A. (2008) Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 19, 209–216.
<https://doi.org/10.1097/CAD.0b013e3282f2d8e4>
37. Lorlatinib (2019) Committee for Medicinal Products for Human Use. European Medicines Agency. Lorviqua. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/lorviqua-epar-public-assessment-report_en.pdf (Accessed 13 March 2023)
38. , B. D., Stocker, S. L., Verougstraete, N., Kocic, D., Galettis, P., Stove, C. P., Reuter, S. E. (2021) Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br. J. Clin. Pharmacol. 87, 227–236.
<https://doi.org/10.1111/bcp.14372>
39. , F., Djebli, N., González-Sales, M., Jaminion, F., Meneses-Lorente, G. (2022) Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. Cancer Chemother. Pharmacol. 89, 363–372.
<https://doi.org/10.1007/s00280-022-04402-w>
40. Mobocertinib (2021) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multi-disciplinary Review and Evaluation NDA 215310 EXKIVITY (mobocertinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf (Accessed 13 March 2023)
41. , A., Groenland, S. L., Scherf-Clavel, O., van Dyk, M., Huisinga, W., Michelet, R., Jaehde, U., Steeghs, N., Huitema, A. D. R., Kloft, C. (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol. 77, 441–464.
<https://doi.org/10.1007/s00228-020-03014-8>
42. Osimertinib (2015) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065orig1s000clinpharmr.pdf (Accessed 13 March 2023)
43. , D., Gibiansky, E., Leonowens, C., O’Hagan, A., Haney, P., Switzky, J., Goodman, V. L. (2014) Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. J. Clin. Pharmacol. 54, 696–706.
<https://doi.org/10.1002/jcph.263>
44. , D., Kassir, N., Chiu, J., Mouksassi, M. S., Leonowens, C., Cox, D., DeMarini, D. J., Gardner, O., Crist, W., Patel, K. (2016) Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother. Pharmacol. 77, 807–817.
<https://doi.org/10.1007/s00280-016-2993-y>
45. , E., Buclin, T., Guidi, M., Quoix, E., Gourieux, B., Decosterd, L. A., Gairard-Dory, A. C., Ubeaud-Séquier, G., Widmer, N. (2015) Erlotinib: Another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature. Ther. Drug Monit. 37, 2–21.
<https://doi.org/10.1097/FTD.0000000000000097>
46. Pralsetinib (2020) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multi-disciplinary Review and Evaluation NDA 213721 GAVRETO (pralsetinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf (Accessed 13 March 2023)
47. Pralsetinib (2021) Committee for Medicinal Products for Human Use. European Medicines Agency. Gavreto. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/gavreto-epar-public-assessment-report_en.pdf (Accessed 13 March 2023)
48. , M., Alvarez, J. C., Saiag, P., Beauchet, A., Funck-Brentano, C., Funck-Brentano, E. (2022) Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600mut melanoma patients. Ann. Dermatol. Venereol. 149, 32–38.
<https://doi.org/10.1016/j.annder.2021.04.005>
49. , T., Puszkiel, A., Cardoso, E., Balakirouchenane, D., Narjoz, C., Arrondeau, J., Fallet, V., Khoudour, N., Guidi, M., Vidal, M., Declèves, X., Csajka, C., Alexandre, J., Cadranel, J., Fabre, E., Wislez, M., Goldwasser, F., Blanchet, B. (2022) Exposure-response analysis of osimertinib in patients with advanced non-small-cell lung cancer. Pharmaceutics 14, 1844.
<https://doi.org/10.3390/pharmaceutics14091844>
50. Selpercatinib (2020) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multi-disciplinary Review and Evaluation NDA 213246 RETEVMO (selpercatinib). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf (Accessed 11 March 2023)
51. , R. L., Miller, K. D., Fuchs, H. E., Jemal, A. (2022) Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33.
<https://doi.org/10.3322/caac.21708>
52. Tepotinib (2021) Committee for Medicinal Products for Human Use. European Medicines Agency. Tepmetko. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report/tepmetko-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
53. Trametinib (2013) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114orig1s000clinpharmr.pdf (Accessed 11 March 2023)
54. , R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., Huitema, A. D. R. (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin. Pharmacol. Ther. 102, 765–776.
<https://doi.org/10.1002/cpt.787>
55. , S., Schnell, D., Ebner, T., Freiwald, M., Stopfer, P. (2017) Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin. Pharmacokinet. 56, 235–250.
<https://doi.org/10.1007/s40262-016-0440-1>
56. , S., Zhao, Y., Wang, X., Huang, Y., Zhang, J., Guo, Y., Li, J., Li, H., Ma, Y., Chen, L., Hu, Z., Huang, M., Zhang, L. (2015) The dissociation of gefitinib trough concentration and clinical outcome in NSCLC patients with EGFR sensitive mutations. Sci. Rep. 5, 12675.
<https://doi.org/10.1038/srep12675>
57. , W., Papasouliotis, O., Jonsson, E. N., Strotmann, R., Girard, P. (2022) Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study. Cancer Chemother. Pharmacol. 89, 655–669.
<https://doi.org/10.1007/s00280-022-04423-5>
58. , H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H., Beijnen, J. H., Huitema, A. D. (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets. Clin. Pharmacokinet. 53, 305–325.
<https://doi.org/10.1007/s40262-014-0137-2>
59. , S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R., Venkatakrishnan, K., Gupta, N. (2021) Single-dose pharmacokinetics and tolerability of the oral epidermal growth factor receptor inhibitor mobocertinib (TAK-788) in healthy volunteers: Low-fat meal effect and relative bioavailability of 2 capsule products. Clin. Pharmacol. Drug Dev. 10, 1028–1043.
<https://doi.org/10.1002/cpdd.951>
60. , Y. Y., Li, S., Zhang, Y., Zhao, H. Y., Liao, H., Guo, Y., Shi, Y. X., Jiang, W., Xue, C., Zhang, L. (2011) The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med. Oncol. 28, 697–702.
<https://doi.org/10.1007/s12032-010-9541-0>
61. , L., Wang, S., Chen, M., Huang, S., Zhang, M., Bao, W., Bao, A., Zhang, P., Guo, H., Liu, Z., Xie, G., Gao, J., Wu, Z., Lou, Y., Fan, G. (2021) Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1175, 122752.
<https://doi.org/10.1016/j.jchromb.2021.122752>
